Recombinant Human AOC3 (C-6His)

Artikelnummer: EBT-EPT191
Artikelname: Recombinant Human AOC3 (C-6His)
Artikelnummer: EBT-EPT191
Hersteller Artikelnummer: EPT191
Alternativnummer: EBT-EPT191-50
Hersteller: ELK Biotechnology
Kategorie: Proteine/Peptide
Alternative Synonym: Membrane primary amine oxidase, Copper amine oxidase, HPAO, Semicarbazide-sensitive amine oxidase, SSAO, Vascular adhesion protein 1, VAP-1, AOC3, VAP1
Recombinant Human Membrane Primary Amine Oxidase is produced by our Mammalian expression system and the target gene encoding Arg28-Asn763 is expressed with a 6His tag at the C-terminus.
Molekulargewicht: Molecular weight: 82.6 KDa. Apparent molecular weight: 90-110 KDa, reducing conditions
UniProt: Q16853
Reinheit: Greater than 95% as determined by reducing SDS-PAGE.
Anwendungsbeschreibung: Endotoxin: Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test. Background: Vascular adhesion protein-1(VAP-1) is a copper amine oxidase with a topaquinone cofactor.VAP-1 is a type II integral membrane protein, but a soluble form of the enzyme is present in human serum, and its level increases in diabetes and some inflammatory liver diseases. VAP-1 catalyzes the oxidative deamination of small primary amines such as methylamine, benzylamine, and aminoacetone in a reaction that produces an aldehyde, ammonia, and H2O2. VAP-1 vascular expression is regulated at sites of inflammation through its release from intracellular granules in which the protein is stored. The adhesive function of VAP-1 has been demonstrated in studies showing that the protein is important for the adherence of certain lymphocyte subtypes to inflamed endothelial tissues. VAP-1 mediated adhesion is involved in the process of leukocyte extravasation, an important feature of inflammatory responses. VAP-1 is considered to be a therapeutic target for diabetes, oxidative stress, and inflammatory diseases